Price Target Motley fool 6/19/2017 article put peak sales at $340 million so with a future market cap of 3 times peak sales divided by 123 million shares I get a share price of $8.29. Article also said FDA decision by April 2018.
BMY take RIGL out ?
Nice upturn from the 2.29 price last week.
Seems like some of the risk is gone now that they got over the hurdle of having their NDA accepted, so a higher price seems fair. Granted they still need the drug approved, but seems like it should be trading at least $3.00 after this news.
So did the FDA accept the NDA? Why is there no press release?
I am thinking abotu buying RIGL, with 98m cash, no debt, almost 90%owned by institutions and not many shares short why the low stock price? 4 deals with big drug cmpanies. What do you shareholders know that I don't? Thanks
biggest buying volume in several weeks. have we hit a bottom?
you could be right gator but that's a lot of conclusions you are jumping to. they could also be raising money because they think fda will pass and they will need $$$ to market a new product.
buying AXSM at $4 is like buying JAZZ at $1 a few years ago now trading at $151 (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $90 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.90
Shares Out: 23.5 Million
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
RIGL filed S7 today for offer to raise 40 million dollars.... probably discount share price 20% (dilution) but the bigger question what that means to the NDA just submitted.... Did receive good or bad news from FDA... imo, they received or anticipate negative news (FDA requires phase 4) .... If the FDA news was good they would've publish it first then raised cash.... raising cash ahead of that announcement is negative ... so I sold for small loss, I will jump back in once dust settles... I like how the reaction was very mild due to the very small ownership % of retails. Good luck to all longs here
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.7 In other words, the correlation coefficient of the other stoc
and if your assertion was correct I'd expect to see higher selling volume.